Drug Profile
Irsogladine/lafutidine
Alternative Names: BRI-1501Latest Information Update: 28 May 2019
Price :
$50
*
At a glance
- Originator Boryung Pharmaceutical
- Class Acetamides; Antiulcers; Cytoprotectives; Gastric antisecretories; Neuroprotectants; Piperidines; Pyridines; Small molecules
- Mechanism of Action Cholinesterase inhibitors; Histamine H2 receptor antagonists; Phosphoric diester hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Gastric ulcer
Most Recent Events
- 28 May 2019 No recent reports of development identified for phase-I development in Gastric-ulcer(In volunteers) in South Korea (PO, Tablet)
- 29 Dec 2016 Boryung Pharmaceutical completes a phase I trial in Gastric ulcer (In volunteers) in South Korea (PO) (NCT02759224)
- 19 May 2016 Chemical information added